Related Experiment Video
Updated: Aug 14, 2026

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
Impact of the COVID-19 Pandemic on Viral Respiratory Testing in Children With Abnormal Urinalysis
Grace Truong1, Sowdhamini S Wallace1, Duc T Nguyen2
1Division of Pediatric Hospital Medicine, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.
Insights
Respiratory viral panels (RVP) use significantly increased in children with abnormal urinalysis (UA) during and after the COVID-19 pandemic. This costly testing showed low antiviral use, indicating a need for better diagnostic stewardship.
Area of Science:
- Pediatric Emergency Medicine
- Infectious Diseases
- Diagnostic Testing
Background:
- Respiratory viral panels (RVP) are frequently used in pediatric emergency departments.
- The utility of RVP in children with abnormal urinalysis (UA) results, particularly for non-respiratory conditions, is questionable.
- Pre-existing overuse of RVP was hypothesized to increase following the COVID-19 pandemic.
Purpose of the Study:
- To evaluate the trends in RVP utilization among children aged 0-24 months with abnormal UA results before, during, and after the COVID-19 pandemic.
- To assess the impact of RVP testing on treatment decisions, specifically antiviral use, and associated healthcare costs.
Main Methods:
- A retrospective cohort study was conducted on 7496 children (0-24 months) with abnormal UA results presenting to a pediatric ED.
- Data were collected for three periods: prepandemic (March 2018-February 2020), pandemic (March 2020-May 2023), and postpandemic (July 2023-May 2025).
- Interrupted time series analysis examined RVP testing trends, with secondary outcomes including ED revisits, antiviral use, and costs.
Main Results:
- RVP testing increased from 25.0% prepandemic to 68.1% during the pandemic and remained high at 66.1% postpandemic.
- There was a significant increase in RVP use during the pandemic compared to prepandemic (P < .001), with no significant change between pandemic and postpandemic periods (P = .14).
- RVP testing was associated with no difference in ED revisits (P = .41), low antiviral use (1.8%), and a total cost of $1,037,978.
Conclusions:
- RVP testing in children with abnormal UA results surged during the COVID-19 pandemic and persisted postpandemic.
- The high cost and limited impact on antiviral prescribing highlight significant opportunities for improving diagnostic stewardship.
- Optimizing RVP utilization in this population is crucial for resource management and appropriate patient care.
Objective:
Respiratory viral panels (RVP) are common, expensive tests that often do not change treatment, especially in children with suspected urinary tract infections. In children with abnormal urinalysis (UA) results, we hypothesize that RVP overuse existed before the COVID-19 pandemic and has risen further after.
Methods:
We conducted a single-center retrospective cohort study of children aged 0 to 24 months who presented to a quaternary care children's emergency department (ED) from March 2018 to May 2025 with abnormal UA results. Children with complex chronic conditions, required intensive care or respiratory support, or sepsis were excluded. The primary outcome was the proportion of children with RVP testing within periods of prepandemic (March 2018-February 2020), pandemic (March 2020-May 2023), and postpandemic (July 2023-May 2025). Secondary outcomes included ED revisits, antiviral use, and cost of testing. We assessed trends in RVP use across the periods using interrupted time series analysis. Cost was measured using Medicaid reimbursement fees.
Results:
Our cohort included 7496 patients. The proportion of all children who received an RVP was 25.0% (95% CI, 23.1-27.0), 68.1% (95% CI, 66.5-69.7), and 66.1% (95% CI, 64.1-68.0) during prepandemic, pandemic, and postpandemic periods, respectively. There was an increase in viral testing during the pandemic compared with prepandemic period (P < .001) but without change between pandemic and postpandemic (P = .14). Viral testing was associated with no differences in ED revisits (P = .41). Only 134 patients (1.8%) received antivirals. The total cost of respiratory viral testing was $1 037 978.
Conclusions:
RVP testing increased during the COVID-19 pandemic in children with abnormal UA results and remained elevated postpandemic. RVP testing was costly and associated with low antiviral use. These results highlight opportunities for diagnostic stewardship.
Related Concept Videos
Urine Studies II: Urine Culture and Sensitivity Test
Urine Studies I: Urinalysis
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Infection II: Pathophysiology